Amendment and Reply Under 37 C.F.R. § 1.111 U.S. Application Serial Number 09/691,504

first immunostimulating molecule; and (b)

a second part comprising antigen presenting cell, which are capable of inducing T-cell activation and which are autologous, syngeneic or allogeneic, pulsed with a preparation comprising enucleated cytosol and cell membranes of cancer cells infected with a recombinant vaccinia virus encoding at least one second immunostimulating molecule.

- 55. (First Amended)A method for eliciting an anti-cancer immune response in a subject, which comprises:
 - administering a first recombinant vaccinia virus encoding at least one first (a) immunostimulating molecule; and
 - (b) administering a composition comprising antigen presenting cells, which are capable of inducing T cell activation and which are autologous, syngeneic or allogeneic, pulsed with a preparation comprising enucleated cytosol and cell membranes of cancer cells infected with a second recombinant vaccinia virus encoding at least one second immunostimulating molecule.

56. (First Amended)The method of claim 55, wherein about 10⁴ to about 10⁸ PFU of the first recombinant vaccinia virus is provided.

- 57. (First Amended)The method of claim 55, wherein about 10⁷ PFU of the first recombinant vaccinia virus is provided.
- 58. (First Amended)The method of claim 55, wherein about 10⁵ to about 10⁷ antigen presenting cells are provided.
- (First Amended)The method of claim 55, wherein about 106 to about 5x106 antigen 59. presenting cells are provided.
- 78. (First Amended) A method of treating cancer in a subject, which comprises:
 - administering a first live recombinant vaccinia virus encoding at least one first (a) immunostimulating molecule; and
 - (b) administering an effective amount of a composition comprising antigen presenting cells and which are autologous, syngeneic or allogeneic, which are capable of inducing T-cell activation, pulsed with a preparation comprising enucleated cytosol and cell membranes of cancer cells infected with a second recombinant vaccinia virus encoding for at least one second immunostimulating molecule.

REMARKS

Favorable reconsideration of the subject application is respectfully requested in view

O, y